FeNO level with the characteristics of all patients, PFT and blood examination were evaluated.
ACO and asthma were comparable. And because it seems that there were undiagnosed ACO in the COPD group, FeNO level of COPD tended to be higher. Methods: We did a review and meta-analysis of randomized controlled trials on anti-interleukin 5 therapy in moderate to severe patients with eosinophilic COPD vs placebo. The primary outcome is annual exacerbation rate. Secondary outcomes include reduction of blood and sputum eosinophilia, improvement in lung function, change in symptom and quality of life scores and adverse events.
Results: This analysis included 4 RCTs (3 for Mepolizumab and 1 for Benralizumab) with a total patient population of 1,236 eosinophilic COPD patients. Compared with placebo, patients on anti-IL5 had a significant reduction in the annual exacerbation rate (mean difference -0.24 [-0.35 to -0.13]) and sputum eosinophilia (mean difference 4.09 [−6.61 There is no significant difference in lung function and Saint George's Respiratory Questionnaire scores. There is a trend toward increased overall adverse events (AEs) with anti-IL5 treatment and a trend toward decreased serious AEs and AEs leading to discontinuation of therapy.
Conclusion: Anti-IL5 agents clearly reduce exacerbation rates and sputum eosinophilia and improve quality of life in patients with eosinophilic COPD. Treatment shows equivocal findings regarding time to exacerbation and safety. Additional trials on other anti-IL5 agents such as Reslizumab may be done to further assess the benefit and safety of these novel agents for COPD. Background and Aims: Chronic obstructive pulmonary disease (COPD), a highly prevalent disease predominantly caused by exposed to cigarette smoke, with no effective treatments. Despite an increased understanding of the pathogenesis of COPD, mechanisms that drive these processes remain incompletely understood.
Methods: To investigate the mechanisms that initiate the COPD, we used a well characterized cigarette smoke exposure mouse model. In vitro, cigarette smoke extract (CSE) was exposed to MLE-12 cells. Mass spectrometry was used to determine the lipid metabolism. To identify the role of fatty acid synthesis (FASN) in the lung, we conditionally deleted FASN in type II cells (AEC2s) in mice.
Results: We found that cigarette smoke exposure for 6 months led to lipid composition altered in the whole lung as well as in AEC2s. FASN is down-regulated by cigarette smoke in AEC2 and cultured cells. mRNA isolated from AEC2s demonstrated that 64% of AEC2s lacked FASN in conditional deleted mice. AEC2s Cells lacking FASN had increased expression of mRNAs associated with lipid synthesis and transport. Lipidomic data indicated that mice deficient in AEC2s led to lipid content changes in the whole lung and AEC2s. Conditional deletion of FASN in AEC2s developed emphysema in aged mice.
Conclusion:
Our results suggest lipid alteration and damaged surfactant is a central mechanism that drives cigarette smoke-induced COPD. Further investigation identify the FASN is a key enzyme regulated lipid homeostasis. Lack of FASN led to the development of emphysema. 
